Archive: Clinical Trials

Patient recruitment is one of the most critical and challenging aspects of clinical trials. Medical contact centers can be beneficial to the entire healthcare industry, but we’re going to focus on how they can help clinical trial participation. These contact centers drive study enrollment by improving the patient recruitment process through patient engagement and education.

Imagine a patient participating in a clinical trial for a new vaccine. They take a half day of PTO to visit the clinic, which is a short 15-minute drive from their home. After an hour visit, they are given $50 as compensation – a reasonable amount which they spend on a nice dinner. This describes

SubjectWell recently fielded a survey engaging over 300 type 2 diabetes patients. The findings showed that diabetes patients demonstrated high overall interest in clinical trial participation, but secondary conditions caused by their diabetes can shift that interest higher or lower. According to the CDC, more than 33 million Americans have type 2 diabetes. As patients’

Minority populations are significantly underrepresented in clinical research. When comparing the FDA’s recent Drug Trial Snapshots data with US Census data, women, white patients, and older patients are shown to be overrepresented in clinical trials. Black patients make up just 8% and Hispanic patients 11% of trial participants — much lower than their general population

For a clinical trial to be successful, patients need to be the top priority. However, language barriers faced during the clinical trial process can often result in lower participation rates of non-English speakers, an unsatisfactory patient experience and, ultimately, imprecise data. In the US, the leading country in clinical trial participation each year, language barriers

At SubjectWell, we have been conducting an ongoing survey since the beginning of the pandemic to understand how patient attitudes toward clinical research participation have been affected. As the coronavirus pandemic continues, we continue to see how the rapidly evolving situation is also changing the clinical trial landscape. The third round of our survey was

In February 2022, SubjectWell announced the expansion of its proven marketplace to include oncology clinical trials, beginning with non-small cell lung cancer (NSCLC). Lung cancer is by far the leading cause of cancer death, and more specifically, the vast majority of lung cancer diagnoses are NSCLC. To develop a better understanding of NSCLC patients’ attitudes

SubjectWell has been providing risk-free patient recruitment for 10 years, building awareness of the benefits of clinical research and offering choice to patients with chronic ambulatory health conditions by screening for multiple studies at once. And now we’re taking our marketplace one step further. In February 2022, SubjectWell expanded our proven clinical trial marketplace to

Parkinson’s disease (PD), a lifelong and progressive neurological condition, affects about one million people in the United States alone. Primary PD symptoms involve motor impairments, like slowness of movement, gait problems, rigidity, and tremors, as well as significant “invisible” non-motor symptoms, cognitive problems, anxiety, depression, sleep disorders, and digestive problems, which can be disabling. Within

Enrolling a diverse pool of patients is often a challenge for sponsors and CROs. Fortunately, digital patient outreach can help boost clinical trial recruitment efforts.